Sakar Healthcare Limited — PPTs, 13-05-2026: Investor Presentation

Sakar Healthcare reported strong financial performance for the quarter and full fiscal year ended March 31, 2026.

**1. Business Performance:** Revenue for the quarter rose 42% YoY to ₹71.10 Cr, with full-year revenue also growing 42% to ₹251.74 Cr. Profitability saw significant improvement; Q4 EBITDA jumped 67% to ₹26.24 Cr (37% margin), and full-year PAT surged 74% to ₹30.48 Cr. This was largely driven by oncology-led growth, new market authorizations, and robust demand across regions. Full-year EPS was ₹13.70.

**2. Growth Drivers or Strategy:** The company's strategic focus on oncology is key, leveraging its vertically integrated API and Finished Dosage Form (FDF) capabilities with EU-GMP approved facilities. A diversified business model, shifting towards higher-margin own brand exports (70%), and a strong pipeline of 55 oncology molecules (32 ready for launch, 12 global Marketing Authorizations) are vital growth accelerators.

**3. Recent Developments:** Sakar has secured over 60 oncology business contracts and received 12 global Marketing Authorizations, including 11 product dossier approvals for key oncology drugs. Technology transfer projects with major pharma partners are actively progressing, with four site variation approvals already granted in the UK and EU.

**5. Management Commentary / Outlook:** Management sees the oncology business as a primary growth engine. They anticipate a stronger FY27, driven by its ramp-up and increasing export traction as approvals translate into launches and supplies.